HCA — HCA Healthcare, Inc.
Is HCA overbought or oversold? Here is the current MarketMoodz read.
HCA Healthcare, Inc. (HCA) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Care Facilities) last closed at $511.73. The rating moved from Neutral to Overbought on November 10, 2026.
- Public ratingOverbought (as of November 17, 2026)
- Last close$511.73
- Last changeMoved from Neutral to Overbought on November 10, 2026
- SectorHealthcare
- IndustryMedical Care Facilities
See all overbought Healthcare stocks →
AI analysis
HCA Healthcare is a scale leader in hospital and ambulatory care with resilient cash generation supported by demographic trends and expanding Medicare Advantage coverage. Near-term catalysts include outpatient expansion, steady elective-procedure demand and disciplined capital allocation, while primary headwinds are reimbursement risk, elevated labor costs and elevated valuation that amplify downside if volumes soften. Market sentiment in the immediate window is cautious but slightly risk-on, providing a constructive backdrop for large-cap healthcare exposure absent abrupt policy changes.
Key factors
- Large national hospital operator with diversified acute-care, outpatient surgery and ambulatory services providing stable and high-margin cash flows
- Favorable demand backdrop from aging population, elective procedure normalization and growing Medicare Advantage enrollment expanding insured volumes
- Scale provides negotiating leverage with payors and ability to invest in efficiency, clinical programs and ambulatory expansion
- Strong free cash flow and balance sheet capacity to fund buybacks, dividends and targeted M&A that support earnings durability
- Current market tone is cautiously risk-on with defensive flows into healthcare, supporting relative outperformance versus cyclicals in near term
Risks
- Reimbursement pressure from Medicare policy changes, Medicaid dynamics, or regulatory reforms that reduce hospital payments
- Sustained labor cost inflation and staffing shortages that compress margins and increase operating expense
- Political and regulatory scrutiny of healthcare (including antitrust or payment-model reforms) that could introduce uncertainty or constrain growth
- High valuation relative to broader market — earnings or utilization misses could produce sharp downside
- Geographic or legal/regulatory exposure at the state level and episodic litigation or compliance costs
See today's live rating, score and targets
Members see the live hourly rating for HCA — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.